Patents by Inventor Kwang-Won Hong
Kwang-Won Hong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240125706Abstract: A surface plasmon resonance imaging apparatus is provided. The surface plasmon resonance imaging apparatus includes a light irradiation unit configured to irradiate polarized light onto a metal coating film provided on one surface of a prism, a light modulator configured to spatially pattern-encode light reflected by the metal coating film and the prism, a light detector configured to detect a pattern-encoded light signal, obtained through pattern-encoding by the light modulator, as a spectral signal, a signal processor configured to spatially decode the spectral signal and analyze a decoded spectral signal to generate characteristic data of a sample provided on the metal coating film, and an output unit configured to output the characteristic data of the sample as a two-dimensional (2D) image.Type: ApplicationFiled: December 29, 2022Publication date: April 18, 2024Applicant: Electronics and Telecommunications Research InstituteInventors: SOOCHEOL KIM, JeongKyun KIM, Hyunseok KIM, Jin Hwa RYU, SO YUNG PARK, Hoe-Sung YANG, KANG BOK LEE, Sun-Hwa LIM, Kwang-Soo CHO, Kyu Won HAN, Sang Gi HONG
-
Patent number: 11944661Abstract: The present invention provides a pharmaceutical composition for prevention or treatment of a stress disease and depression, the pharmaceutical composition be safely useable without toxicity and side effects by using an extract of leaves of Vaccinium bracteatum Thunb., which is natural resource of Korea, so that the reduction of manufacturing and production costs and the import substitution and export effects can be expected through the replacement of a raw material for preparation with a plant inhabiting in nature.Type: GrantFiled: February 7, 2018Date of Patent: April 2, 2024Assignee: JEONNAM BIOINDUSTRY FOUNDATIONInventors: Chul Yung Choi, Dool Ri Oh, Yu Jin Kim, Eun Jin Choi, Hyun Mi Lee, Dong Hyuck Bae, Kyo Nyeo Oh, Myung-A Jung, Ji Ae Hong, Kwang Su Kim, Hu Won Kang, Jae Yong Kim, Sang O Pan, Sung Yoon Park, Rack Seon Seong
-
Publication number: 20210055305Abstract: Provided are a peptide consisting of an amino acid sequence of SEQ ID NO: 3, which is a novel epitope of immunoglobulin E (IgE), and an anti-IgE antibody binding to the peptide, in which the peptide and the antibody may be applied for diagnosing an allergic disease or research on a therapeutic agent therefor. In addition, provided are a kit for analyzing IgE in a sample containing the antibody and a method of diagnosing an allergic disease using the kit, which may perform qualitative analysis to determine the presence or absence of a typical inhalant and food allergies with high incidence in Koreans, and diagnose an allergy within a short period after blood collection.Type: ApplicationFiled: April 5, 2019Publication date: February 25, 2021Inventors: Bong Hui KIM, Eun Young PARK, Ha Kyung JANG, Kwang Won HONG
-
Publication number: 20190153117Abstract: Disclosed are epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-?, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.Type: ApplicationFiled: January 28, 2019Publication date: May 23, 2019Applicants: GREEN CROSS CORPORATION, MOGAM BIOTECHNOLOGY RESEARCH INSTITUTEInventors: Se-Ho Kim, Kwang-Won Hong, Ki-Hwan Chang, Min-Soo Kim, Mi-Jung Lee, Jong-Hwa Won, Min-Kyu Hur, Hyun-Soo Cho, Ji-Ho Yoo
-
Publication number: 20170260257Abstract: The present invention provides an antibody that binds to the surface antigen (HBsAg) of hepatitis B virus (HBV) to neutralize the hepatitis B virus. The surface antigen-binding site of the antibody was found to play a very important role in viral replication, and when a mutation in the site occurs, viral replication is significantly inhibited, and thus at least HBV virus cannot cause a mutation in the site. In the present invention, it was confirmed by the use of patient-derived virus that the antibody of the present invention binds to either YMDD mutant hepatitis B virus, produced by conventional viral replication inhibitors, or G145R HBsAg mutants to which plasma-derived HBIG (hepatitis B immunoglobulin) does not bind. In addition, the in vivo effect of the antibody of the present invention was examined using chimpanzees which are unique animal models for hepatitis B virus. As a result, it was found that the antibody has the effect of neutralizing even wild-type hepatitis B virus in the in vivo model.Type: ApplicationFiled: May 16, 2017Publication date: September 14, 2017Inventors: Se-Ho Kim, Kwang-Won Hong, Wong-Won Shin, Ki Hwan Chang
-
Patent number: 9683029Abstract: The present invention provides an antibody that binds to the surface antigen (HBsAg) of hepatitis B virus (HBV) to neutralize the hepatitis B virus. The surface antigen-binding site of the antibody was found to play a very important role in viral replication, and when a mutation in the site occurs, viral replication is significantly inhibited, and thus at least HBV virus cannot cause a mutation in the site. In the present invention, it was confirmed by the use of patient-derived virus that the antibody of the present invention binds to either YMDD mutant hepatitis B virus, produced by conventional viral replication inhibitors, or G145R HBsAg mutants to which plasma-derived HBIG (hepatitis B immunoglobulin) does not bind. In addition, the in vivo effect of the antibody of the present invention was examined using chimpanzees which are unique animal models for hepatitis B virus. As a result, it was found that the antibody has the effect of neutralizing even wild-type hepatitis B virus in the in vivo model.Type: GrantFiled: July 8, 2013Date of Patent: June 20, 2017Assignee: GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Kwang-Won Hong, Wong-Won Shin, Ki Hwan Chang
-
Publication number: 20170145107Abstract: Disclosed are epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-?, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.Type: ApplicationFiled: February 6, 2017Publication date: May 25, 2017Applicants: GREEN CROSS CORPORATION, MOGAM BIOTECHNOLOGY RESEARCH INSTITUTEInventors: Se-Ho KIM, Kwang-Won HONG, Ki-Hwan CHANG, Min-soo KIM, Mi-jung LEE, Jong-hwa WON, Min-Kyu HUR, Hyun-Soo CHO, Ji-Ho YOO
-
Publication number: 20160311862Abstract: Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition including an antibody to the foregoing epitope or a vaccine composition including the epitope has very low possibility of causing degradation of curing efficacy due to HBV mutation, thus being very useful for HBV treatment.Type: ApplicationFiled: July 11, 2016Publication date: October 27, 2016Applicant: GREEN CROSS CORPORATIONInventors: Se-Ho KIM, Kwang-Won HONG, Yong-Won SHIN, Ki Hwan CHANG, Min-soo KIM, Jung-Ae IM
-
Patent number: 9415100Abstract: Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition including an antibody to the foregoing epitope or a vaccine composition including the epitope has very low possibility of causing degradation of curing efficacy due to HBV mutation, thus being very useful for HBV treatment.Type: GrantFiled: July 25, 2011Date of Patent: August 16, 2016Assignee: GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Kwang-Won Hong, Yong-Won Shin, Ki Hwan Chang, Min-Soo Kim, Jung-Ae Im
-
Patent number: 9200062Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.Type: GrantFiled: May 21, 2014Date of Patent: December 1, 2015Assignee: GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Kyung Hwan Ryoo, Dong Hyuck Seo, Jean Man Kim, Yong Nam Shin, Sunmi Koo, Jung-Ae Lim, Mijung Lee, Yeon Kyung Lee, Misun Seo
-
Patent number: 9134287Abstract: The present invention relates to a system for providing food expiration date information using a TTI (time temperature integrator) and a method for providing food expiration date information using the same. The system for providing the food expiration date information and the method for providing the food expiration date information using the same of the present invention includes: an input unit for receiving TTI information, food information, and distribution history information; a calculation unit for producing a TTI indication value corresponding to an expiration date of the food; and an output unit which determines and outputs a color corresponding to the expiration date of the food among stages of colors which can be expressed through the TTI according to time and temperature conditions using the TTI indication value.Type: GrantFiled: April 27, 2011Date of Patent: September 15, 2015Assignee: Dongguk University Industry-Academic Cooperation FoundationInventors: Seung Ju Lee, Kwang Won Hong, Jin Young Han, Seung Won Jung
-
Publication number: 20150231220Abstract: The present invention relates to epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes provided by the present invention are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-a, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.Type: ApplicationFiled: March 27, 2013Publication date: August 20, 2015Applicants: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE, GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Kwang-Won Hong, Ki Hwan Chang, Min-soo Kim, Mi-Jung Lee, Jong-Hwa Won, Min-Kyu Hur, Hyun-Soo Cho, Ji-Ho Yoo
-
Publication number: 20150166637Abstract: The present invention provides an antibody that binds to the surface antigen (HBsAg) of hepatitis B virus (HBV) to neutralize the hepatitis B virus. The surface antigen-binding site of the antibody was found to play a very important role in viral replication, and when a mutation in the site occurs, viral replication is significantly inhibited, and thus at least HBV virus cannot cause a mutation in the site. In the present invention, it was confirmed by the use of patient-derived virus that the antibody of the present invention binds to either YMDD mutant hepatitis B virus, produced by conventional viral replication inhibitors, or G145R HBsAg mutants to which plasma-derived HBIG (hepatitis B immunoglobulin) does not bind. In addition, the in vivo effect of the antibody of the present invention was examined using chimpanzees which are unique animal models for hepatitis B virus. As a result, it was found that the antibody has the effect of neutralizing even wild-type hepatitis B virus in the in vivo model.Type: ApplicationFiled: July 8, 2013Publication date: June 18, 2015Inventors: Se-Ho Kim, Kwang-Won Hong, Wong-Won Shin, Ki Hwan Chang
-
Publication number: 20140302598Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.Type: ApplicationFiled: May 21, 2014Publication date: October 9, 2014Inventors: Se-Ho KIM, Ki Hwan CHANG, Kwang-Won HONG, Yong-Won SHIN, Min-soo KIM, Hae-Won LEE, Kyung Hwan RYOO, Dong Hyuck SEO, Jean Man KIM, Yong Nam SHIN, Sunmi KOO, Jung-Ae LIM, Mijung LEE, Yeon Kyung LEE, Misun SEO
-
Patent number: 8840895Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.Type: GrantFiled: July 8, 2010Date of Patent: September 23, 2014Assignee: Green Cross CorporationInventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Kyung Hwan Ryoo, Dong Hyuck Seo, Jean Man Kim, Yong Nam Shin, Sunmi Koo, Jung-Ae Lim, Mijung Lee, Yeon Kyung Lee, Misun Seo
-
Patent number: 8748175Abstract: Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.Type: GrantFiled: November 2, 2009Date of Patent: June 10, 2014Assignee: Green Cross CorporationInventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Yong Nam Shin, Kyung Hwan Ryoo, Dong Hyuck Seo, Jong-Hwa Won, Min-Kyu Hur
-
Publication number: 20140112923Abstract: Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition including an antibody to the foregoing epitope or a vaccine composition including the epitope has very low possibility of causing degradation of curing efficacy due to HBV mutation, thus being very useful for HBV treatment.Type: ApplicationFiled: July 25, 2011Publication date: April 24, 2014Applicant: GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Kwang-Won Hong, Yong-Won Shin, Ki Hwan Chang, Min-Soo Kim, Jung-Ae Im
-
Publication number: 20130209615Abstract: The present invention relates to a system for providing food expiration date information using a TTI (time temperature integrator) and a method for providing food expiration date information using the same. The system for providing the food expiration date information and the method for providing the food expiration date information using the same of the present invention includes: an input unit for receiving TTI information, food information, and distribution history information; a calculation unit for producing a TTI indication value corresponding to an expiration date of the food; and an output unit which determines and outputs a color corresponding to the expiration date of the food among stages of colors which can be expressed through the TTI according to time and temperature conditions using the TTI indication value.Type: ApplicationFiled: April 27, 2011Publication date: August 15, 2013Applicant: Dongguk University Industry-Academic Cooperation FoundationInventors: Seung Ju Lee, Kwang Won Hong, Jin Young Han, Seung Won Jung
-
Publication number: 20120264921Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.Type: ApplicationFiled: July 8, 2010Publication date: October 18, 2012Applicant: GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Kyung Hwan Ryoo, Dong Hyuck Seo, Jean Man Kim, Yong Nam Shin, Sunmi Koo, Jung-Ae Lim, Mijung Lee, Yeon Kyung Lee, Misun Seo
-
Publication number: 20120231021Abstract: Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.Type: ApplicationFiled: November 2, 2009Publication date: September 13, 2012Applicant: GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Yong Nam Shin, Kyung Hwan Ryoo, Dong Hyuck Seo